Morgan Stanley Keeps Buy Rating on Gilead Sciences

Morgan Stanley has maintained its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and kept its price target at $168. The research firm's positive view is based on several factors, including the company's growth outlook and the Yeztugo launch trajectory. Morgan Stanley sees Yeztugo as a key driver of the company's growth in the medium term. Gilead Sciences, Inc. (NASDAQ:GILD) has raised its 2026 sales guidance for Yeztugo.

Yeztugo and FDA Approval Process

■On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the US Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for a 300 mg tablet version of Yeztugo (lenacapavir). The company is seeking approval for the drug as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027.

■Lenacapavir tablets are already approved as part of the Yeztugo treatment regimen for an initial loading dose and as a bridge therapy when the every-six-month injections are delayed. If the new application is approved, once-weekly oral Yeztugo would become the first long-acting oral PrEP treatment.

Investment Interest and Market Performance

■Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation.

■Investors are following Gilead Sciences, Inc. (NASDAQ:GILD)'s growth potential and the launch of new drugs like Yeztugo. Morgan Stanley's positive view supports the company's growth expectations.

The growth potential of Gilead Sciences, Inc. (NASDAQ:GILD) and the launch of Yeztugo play a crucial role in the company's future success. However, investors should consider other factors and make informed investment decisions while closely monitoring market conditions.